Weekly measles cases hit new record amid worst outbreak since 1990s
Weekly measles cases have set a new record, according to figures published Friday by the U.S. Centers for Disease Control and Prevention, topping the peak of an outbreak in 2019 that ranked as the worst since the 1990s.
The number of cases that had their symptoms start during the week of March 30 has grown to 111, according to the agency's latest update. Authorities backdate newly reported measles cases based on when their rash began, to account for delays in reporting and diagnosis.
That tops the 102 cases reported for the week of March 23, 2019, at the height of that year's wave. By the end of 2019, measles cases that year added up to the largest annual tally since endemic spread of the virus was declared eliminated in 2000.
This year, the majority of cases are from an ongoing outbreak in Texas and neighboring states, which is now larger than any other single outbreak since the virus was eliminated. There have been 11 other local outbreaks of measles within the U.S. this year, up from 10 last week.
While the pace of new cases looks to have declined in Texas, officials caution it is too soon to say whether the outbreak is truly ending.
"We look at the trends over time and we'd want to see several weeks of decline. New cases sometimes get reported to public health up to a week after someone was tested, especially if the test was done at a commercial lab," Lara Anton, a spokesperson for the Texas Department of State Health Services, told CBS News in a statement.
Anton said authorities are also watching to see if travel from the Easter holiday weekend last month will result in an increase.
"Cases from travel that weekend would likely start to be reported in the next week or two," Anton said.
This year's tally of cases is likely an undercount, officials and experts have said, citing anecdotes of unreported infections. The unusually high severity of this year's wave also suggests many mild cases of spread are going undiagnosed.
For example, authorities in Canada have confirmed more than 1,000 measles cases so far this year, after record outbreaks there. The U.S. has tallied at least 935 this year, according to the CDC.
In Canada, 7% of cases have resulted in hospitalizations, less than the 13% of cases that have resulted in hospitalizations in the U.S. Three Americans have also died from measles so far this year, compared to none in Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Botox may increase your face value — but you're better off trying this move that doesn't cost a cent, scientists say
Dolly Parton was right. Botox may increase face value for a growing number of Americans, including celebs like Nicole Kidman and Meghan Trainor — but when it comes to making yourself desirable to a prospective partner, researchers say smiling can be even more effective. New research suggests that the popular cosmetic injections do increase users' curb appeal — but when respondents in a survey were asked to rate an array of strange faces, those with upturned lips beat those who merely plumped them up. 4 The research found that smiling could be more effective at enhancing visual appeal than filler injections (pictured). Stasique – Scientists at Tilburg University in The Netherlands also reported that Botox users were likely to be seen as one-night stand prospects — and that getting the costly jabs weren't necessarily useful to those hoping to be taken more seriously as viable life partners. The illusion-shattering findings, published in the journal 'Perception,' come amid a worldwide uptick in Botox usage. Usage of the injectable 'tweakment' has become so frequent that people are actually developing an immunity. Researchers set out to test if people who undergo Botox and other filler treatments are perceived 'more positively by others,' per study co-author Dr. Bastian Jaeger, who claimed that 'existing research on the effectiveness of these treatments is not very strong.' To see if it's worth literally putting one's money where their mouth is, the scientists followed 114 participants who underwent Botox and dermal filler treatments, the Times Of London reported. 4 Study authors found that while Botox can make you more attractive as a mate, it won't necessarily get you to happily ever after any faster. Vasyl – They then asked around 3,000 people to rate their before and after pics on a 7-point attractiveness scale. After reviewing said snaps, which were shot carefully to keep the lighting, expression and other factors consistent across the pics, participants overwhelmingly found that Botox does indeed boost people's visual appeal. 'This difference was rather small: a 0.07-point change in our 7-point attractiveness scale on average,' explained Dr. Jaeger per the Daily Mail. 'This means that on average, a person who was rated a 4 out of 7 on attractiveness before the treatment might be rated a 4.07 out of 7 after treatment.' 4 Participants were asked to evaluate the before-and-after pics of Botox recipients. Sage Journals There was also an increase of 0.13 with regards to how youthful the participants were thought of. However, this paled in comparison to another, less expensive way of enhancing one's attractiveness: smiling. Researchers found that turning one's frown upside down — and not cosmetically — caused one's so-called hotness to soar by 0.4 points, six times more than Botox. 4 'We did not see any benefits of treatment on how competent, intelligent, charismatic, friendly or trustworthy people were perceived to be,' said Jaeger. Drobot Dean – Meanwhile, applying makeup gave people's perceived looks a boost of 0.6 points compared to the filler treatment, which starts at around $300 for a simple forehead injection and involves obstructing nerve signals to muscles, relaxing them and curbing wrinkles. There was another major caveat to alleged Botox-enhanced hotness. While the aesthetic accelerant increased people's desirability as a short-term fling prospect and as a platonic pal — a rise of 0.09 in both categories — there was no statistical improvement in how they were seen as long-term partners. It's unclear why Botox didn't up people's image as soulmate material, but scientists noted that the jabs had no effect on the perception of character traits either. 'We did not see any benefits of treatment on how competent, intelligent, charismatic, friendly or trustworthy people were perceived to be,' said Jaeger. Interestingly, while small amounts of botox did not significantly enhance physical appeal, many people report that, 'after treatment, they find it easier to make friends and that they make a better impression on others,' per Jaeger. Dr. Jaeger attributed this phenomenon to a placebo effect of sorts. 'It is plausible that people have more success socially, not because they look different and people treat them differently, but because they think they do and act more confidently around others (sort of a self-fulfilling prophecy),' he said.
Los Angeles Times
an hour ago
- Los Angeles Times
California petitions FDA to undo RFK Jr.'s new limits on abortion pill mifepristone
California and three other states petitioned the U.S. Food and Drug Administration Thursday to ease its new restrictions on the abortion pill mifepristone, citing the drug's proven safety record and arguing the new limits are unnecessary. 'The medication is a lifeline for millions of women who need access to time-sensitive, critical healthcare — especially low-income women and those who live in rural and underserved areas,' said California Atty. Gen. Rob Bonta, who filed the petition alongside the attorneys general of Massachusetts, New York and New Jersey. The petition cites Senate testimony by Health and Human Services Secretary Robert F. Kennedy Jr. last month, in which Kennedy said he had ordered FDA administrator Martin Makary to conduct a 'complete review' of mifepristone and its labeling requirements. The drug, which can be received by mail, has been on the U.S. market for 25 years and taken safely by millions of Americans, according to experts. It is the most common method of terminating a pregnancy in the U.S., with its use surging after the Supreme Court overturned Roe vs. Wade in 2022. The Supreme Court upheld access to the drug for early pregnancies under previous FDA regulations last year, but it has remained a target of anti-abortion conservatives. The Trump administration has given Kennedy broad rein to shake up American medicine under his 'Make America Healthy Again' banner, and Kennedy has swiftly rankled medical experts by using dubious science — and even fake citations — to question vaccine regimens and research and other longstanding public health measures. At the Senate hearing, Kennedy cited 'new data' from a flawed report pushed by anti-abortion groups — and not published in any peer-reviewed journal — to question the safety of mifepristone, calling the report 'alarming.' 'Clearly, it indicates that, at very least, the label should be changed,' Kennedy said. Sen. Josh Hawley (R-Mo.) on Monday posted a letter from Makary to X, in which Makary wrote that he was 'committed to conducting a review of mifepristone' alongside 'the professional career scientists' at the FDA. Makary said he could not provide additional information given ongoing litigation around the drug. The states, in their 54-page petition, wrote that 'no new scientific data has emerged since the FDA's last regulatory actions that would alter the conclusion that mifepristone remains exceptionally safe and effective,' and that studies 'that have frequently been cited to undermine mifepristone's extensive safety record have been widely criticized, retracted, or both.' Democrats have derided Kennedy's efforts to reclassify mifepristone as politically motivated and baseless. 'This is yet another attack on women's reproductive freedom and scientifically-reviewed health care,' Gov. Gavin Newsom said the day after Kennedy's Senate testimony. 'California will continue to protect every person's right to make their own medical decisions and help ensure that Mifepristone is available to those who need it.' Bonta said Thursday that mifepristone's placement under the FDA's Risk Evaluation and Mitigation Strategy program for drugs with known, serious side effects — or REMS — was 'medically unjustified,' unduly burdened patient access and placed 'undue strain on the nation's entire health system.' He said mifepristone 'allows people to get reproductive care as early as possible when it is safest, least expensive, and least invasive,' is 'so safe that it presents lower risks of serious complications than taking Tylenol,' and that its long safety record 'is backed by science and cannot be erased at the whim of the Trump Administration.' The FDA has previously said that fewer than 0.5% of women who take the drug experience 'serious adverse reactions,' and deaths are exceedingly rare. The REMS program requires prescribers to add their names to national and local abortion provider lists, which can be a deterrent for doctors given safety threats, and pharmacies to comply with complex tracking, shipping and reporting requirements, which can be a deterrent to carrying the drug, Bonta said. It also requires patients to sign forms in which they attest to wanting to 'end [their] pregnancy,' which Bonta said can be a deterrent for women using the drug after a miscarriage — one of its common uses — or for those in states pursuing criminal penalties for women seeking certain abortion care. Under federal law, REMS requirements must address a specific risk posed by a drug and cannot be 'unduly burdensome' on patients, and the new application to mifepristone 'fails to meet that standard,' Bonta said. The states' petition is not a lawsuit, but a regulatory request for the FDA to reverse course, the states said. If the FDA will not do so nationwide, the four petitioning states asked that it 'exercise its discretion to not enforce the requirements' in their states, which Bonta's office said already have 'robust state laws that ensure safe prescribing, rigorous informed consent, and professional accountability.'
The Hill
an hour ago
- The Hill
Dr. Oz on Medicaid cuts: People should ‘prove that they matter'
Center for Medicare and Medicaid Services (CMS) Administrator Mehmet Oz defended President Trump's 'big, beautiful bill' over criticism that millions of people could lose health coverage, saying those who would face new work requirements should 'prove that they matter.' Oz made the comments during an interview on Fox Business on Wednesday, arguing that when Medicaid was created in the 1960s lawmakers did not include work requirements because it 'never dawned on anybody that able-bodied people who work would be on Medicaid.' 'We're asking that able-bodied individuals who are able to go back to work at least try to get a job or at least volunteer or take care of loved-one who needs help or go back to school,' he said. 'Do something that shows you have agency over your future.' If Americans are willing to do that, he added, they should be able to be enrolled or stay enrolled in Medicaid. 'But if you are not willing to do those things, we are going to ask you to do something else. Go on the exchange, or get a job and get onto regular commercial insurance. But we are not going to continue to pay for Medicaid for those audiences.' 'Go out there, do entry-level jobs, get into the workforce, prove that you matter. Get agency into your own life,' he added. 'It's a much more enjoyable experience if you go through life thinking you are in control of your destiny and you will get better insurance at the same time.' Thank you for signing up! Subscribe to more newsletters here Close to 11 million people would lose health insurance coverage if the House Republican tax bill passes in the Senate, mainly due to cuts to Medicaid and the Affordable Care Act (ACA), according to analysis from the nonpartisan Congressional Budget Office (CBO). Trump's sprawling agenda bill calls for trillions of dollars' worth of tax cuts, with offsets from sweeping cuts to federal benefit programs, primarily Medicaid. The bill would reduce federal Medicaid spending by $793 billion, according to an analysis from healthcare policy nonprofit KFF. Most of those savings stem from new work requirements for adults trying to enroll in the public health insurance program and more frequent eligibility checks. The bill calls for states to impose work requirements for childless adults between the ages of 19 and 64, with some exceptions, to be eligible for Medicaid. Adults would be required to work or volunteer at least 80 hours a month beginning in December 2026 to qualify for the public health insurance program. Many Trump allies in Congress have sought to downplay the impact of the Medicaid reforms, denying it will reduce access to the program. Meanwhile, several Senate Republicans have raised alarm over Medicaid cuts. Office of Management and Budget Director Russell Vought recently told CNN's Dana Bash that concerns over the bill are 'ridiculous.' 'This bill will preserve and protect the programs, the social safety net, but it will make it much more common sense,' he said. 'No one will lose coverage as a result of the bill.' Democrats have pushed hard against the proposed cuts, while GOP senators such as Lisa Murkowski (Alaska), Susan Collins (Maine) and Josh Hawley (Mo.) have pushed for changes to the bill passed by the House last month.
